News & Media

Boehringer Ingelheim News, Press Releases & Information

Quick access to the latest company news, including corporate, research & development and human pharmaceuticals for members of the media.

Press Release Subscription

Please submit the form below to receive press releases via email.

Information for...

PRESS RELEASE 11 Oct 2018 at 08:00

FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Read more on
FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
PRESS RELEASE 10 Oct 2018 at 06:30

New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Read more on
New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease
PRESS RELEASE 04 Oct 2018 at 11:15

Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial

Read more on
Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial
- Press Release
PRESS RELEASE 04 Oct 2018 at 06:30

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

Read more on Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
PRESS RELEASE 26 Sep 2018 at 09:00

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Read more on Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
PRESS RELEASE 25 Sep 2018 at 09:15

Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Read more on
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)
PRESS RELEASE 17 Sep 2018 at 08:00

New study results provide evidence that Ofev^{^®} (nintedanib) slows progression of IPF beyond four years with consistent safety

Read more on
New study results provide evidence that Ofev^{^®} (nintedanib) slows progression of IPF beyond four years with consistent safety
- Press Release
PRESS RELEASE 13 Sep 2018 at 02:00

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Read more on Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
PRESS RELEASE 12 Sep 2018 at 08:00

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Read more on Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
PRESS RELEASE 04 Sep 2018 at 08:00

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Read more on Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
PRESS RELEASE 06 Aug 2018 at 02:30

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Read more on Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
PRESS RELEASE 01 Aug 2018 at 08:00

Boehringer Ingelheim achieves modest growth in the first half of 2018

Read more on Boehringer Ingelheim achieves modest growth in the first half of 2018
- Press Release
PRESS RELEASE 19 Jul 2018 at 08:00

Boehringer Ingelheim and Lilly announce Tradjenta’s CARMELINA^{^®} cardiovascular outcome trial meets primary endpoint

Read more on
Boehringer Ingelheim and Lilly announce Tradjenta’s CARMELINA^{^®} cardiovascular outcome trial meets primary endpoint
PRESS RELEASE 25 Jun 2018 at 08:00

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Read more on Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
PRESS RELEASE 23 Jun 2018 at 10:00

Jardiance^{^®} reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Read more on
Jardiance^{^®} reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
PRESS RELEASE 22 Jun 2018 at 08:00

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Read more on Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
- Press Release
PRESS RELEASE 31 May 2018 at 09:00

Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Read more on
Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
PRESS RELEASE 21 May 2018 at 14:00

Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018

Read more on
Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018
PRESS RELEASE 04 May 2018 at 08:00

Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide

Read more on
Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide
PRESS RELEASE 25 Apr 2018 at 08:30

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Read more on Boehringer Ingelheim R&D pushes to transcend disease boundaries

Search form

News & Media

Boehringer Ingelheim News, Press Releases & Information

Press Release Subscription